Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735787 · ClinicalTrials.gov registry record · Phase 4
Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
A Phase 4 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
NCT00735787 is a Phase 4 study that has completed, run by Abbott. The registered enrollment target is 81 participants.
The verdict
NCT00735787, a Phase 4 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
Study Summary
Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.
Interventions
- BIOLOGICAL Adalimumab
- BIOLOGICAL Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00735787
The ClinicalTrials.gov registry entry for NCT00735787 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adalimumab is the first listed.
NCT00735787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00735787 about?
NCT00735787 is a clinical study titled "Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet". Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.
What is the current status of trial NCT00735787?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2008-08. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00735787?
The interventions under investigation include: Adalimumab (BIOLOGICAL), Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT00735787?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.